Our aim was to establish which of the current and novel storage fluids caused the least harm to the endothelium of the saphenous vein.
Methods
Unmanipulated samples of saphenous vein were obtained. This vein was exposed to four fluids, DuraGraft®, Plasma-Lyte, autologous blood and sodium chloride, and a control medium. The expression of endothelial selectin (E-selectin) and endothelial nitric oxide synthase (eNOS) was measured using confocal microscopy.
Results
We identified and quantified platelet endothelial cell adhesion molecules, vascular cell adhesion molecules and endothelial nitric oxide synthase 3 on the endothelium. The results were widely variable. The protein expression of endothelial selectin (p = .17) and endothelial nitric oxide synthase 3 (p = .73) showed no statistically significant differences in levels of preservation when the different solutions were compared.
Conclusions
In this study, we could not determine that any of the solutions were superior at preserving saphenous vein endothelium.
HarskampREWilliamsJBHillRC, et al.Saphenous vein graft failure and clinical outcomes: toward a surrogate end point in patients following coronary artery bypass surgery?Am Heart J2013; 165(5): 639–643.
3.
ThatteHSKhuriSF. The coronary artery bypass conduit: I. Intraoperative endothelial injury and its implication on graft patency. Ann Thorac Surg2001; 72(s22): S2245–S2252.
4.
OsgoodMHockingKMVoskresenskyIV, et al.Surgical vein graft preparation promotes cellular dysfunction, oxidative stress and intimal hyperplasia in human saphenous vein. J Vasc Surg2014; 60(1): 202–211.
5.
LawrieGMWeilbacherDEHenryPD. Endothelium-dependent relaxation in human saphenous vein grafts. Effects of preparation and clinicopathologic correlations. J Thorac Cardiovasc Surg1990; 100(4): 612–620.
ThatteHSRousouLHussainiBE, et al.Development and evaluation of a novel solution, Somah, for the procurement and preservation of beating and nonbeating donor hearts for transplantation. Circulation2009; 120(17): 1704–1713. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.108.808907
8.
LopesRWilliamsJBMehtaRH, et al.Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J2012; 164(3): 379–386. https://www.sciencedirect.com/science/article/abs/pii/S0002870312003754
PerraultLPCarrierMVoisineP, et al.Sequential multidetector computed tomography assessments after venous graft treatment solution in coronary artery bypass grafting. J Thorac Cardiovasc Surg2019; 161(1): 96–106. DOI: 10.1016/j.jctvs.2019.10.115.
11.
HaimeMRobertRMKatherineEK, et al.Relationship between intra-operative vein graft treatment with DuraGraft or saline and clinical outcomes after coronary artery bypass grafting. Expert Rev Cardiovasc Ther2018; 16(12): 963–970. https://pubmed.ncbi.nlm.nih.gov/30285502/
GundrySRJonesMIshiharaT, et al.Optimal preparation techniques for human saphenous vein grafts. Surgery1980; 88(6): 785–794.
15.
SantoliEDi MattiaDBoldoriniR, et al.University of Wisconsin solution and human saphenous vein graft preservation: preliminary anatomic report. Eur J Cardio Thorac Surg1993; 7(10): 548–552.
16.
WilbringMSemsMTBirgitZ, et al.Even short-time storage in physiological saline solution impairs endothelial vascular function of saphenous vein grafts. Eur J Cardio Thorac Surg2011; 40(4): 811–815. https://academic.oup.com/ejcts/article/40/4/811/447744
17.
GoldmanSZadinaKKrasnickaB, et al.Predictors of graft patency 3 Years after coronary artery bypass graft surgery. Department of veterans affairs cooperative study group No.297. J Am Coll Cardiol1997; 29(7): 1563–1568.
Korkmaz-IcozSBelindaBJasminS, et al.Graft preservation solution DuraGraft® alleviates vascular dysfunction following in vitro ischaemia/reperfusion injury in rats. Pharmaceuticals2021; 14(10): 1028. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538682/
20.
Ben AliWVoisinePOlsenPS, et al.DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within- patient randomised multicentre trial. Open Heart2018; 5(1): e000780. https://openheart.bmj.com/content/openhrt/5/1/e000780.full.pdf
21.
CaliskanESandnerSMisfeldM, et al.A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry. J Cardiothorac Surg2019; 14(1): 174. https://cardiothoracicsurgery.biomedcentral.com/articles/10.1186/s13019-019-1010-z
22.
AschacherTBaranyiUAschacherO, et al.A novel endothelial damage inhibitor reduces oxidative stress and improves cellular integrity in radial artery grafts for coronary artery bypass. Front Cardiovasc Med2021; 8: 736503. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527012/
23.
TsakokMMontgomery-TaylorSTsakokT. Storage of saphenous vein grafts prior to coronary artery bypass grafting: is autologous whole blood more effective than saline in preserving graft function?Interact Cardiovasc Thorac Surg2012; 15: 720–725.
